Alzamend Neuro (NASDAQ:ALZN) Stock Price Up 2.5%

Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Rating)’s stock price rose 2.5% during trading on Tuesday . The stock traded as high as $0.64 and last traded at $0.63. Approximately 307,034 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 354,706 shares. The stock had previously closed at $0.62.

Alzamend Neuro Price Performance

The company’s 50 day simple moving average is $0.85 and its 200 day simple moving average is $0.99.

Institutional Investors Weigh In On Alzamend Neuro

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALZN. Bank of America Corp DE purchased a new stake in shares of Alzamend Neuro during the 1st quarter worth approximately $35,000. Renaissance Technologies LLC purchased a new stake in shares of Alzamend Neuro during the 2nd quarter worth approximately $56,000. BlackRock Inc. purchased a new stake in shares of Alzamend Neuro during the 3rd quarter worth approximately $709,000. Finally, Vanguard Group Inc. increased its stake in shares of Alzamend Neuro by 6,642.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,095,775 shares of the company’s stock worth $4,874,000 after purchasing an additional 4,035,028 shares during the last quarter. Hedge funds and other institutional investors own 0.95% of the company’s stock.

About Alzamend Neuro

(Get Rating)

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.